The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.
about
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutationsMayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypesMutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaAcquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.Update on cytogenetic and molecular changes in myelodysplastic syndromes.Mutations in epigenetic regulators in myelodysplastic syndromes.Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.Highly variable mutational profile of ASXL1 in myelofibrosis.Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach.ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.ASXL1 mutations in Chinese patients with essential thrombocythemia.ASXL1 mutations in primary and secondary myelofibrosis.A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of casesMolecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevanceClinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era
P2860
Q26768600-23AF42A0-98B3-4FDF-A3BD-17E6ECFB15FDQ27851679-A787CBFF-BC8D-4F98-924E-71D1E9039D20Q27851909-E1E7E643-9DD5-46E1-B8C8-9495FFE673FFQ28590040-0E301F5F-3046-4884-A3CA-A20F4367D343Q33406648-D998E335-6C09-430F-9315-D6563BE8F3F9Q34384728-12604349-7E9D-43B7-A419-6DB3896A628EQ34393208-53D369D1-8BB5-4651-BB26-A06E1C4A09F6Q35265880-51BE38FD-0162-4B5C-9B7E-24BFCFB38BC4Q35346433-44134C03-6742-4D9A-A34A-10D2DFA2A7C3Q35654081-160B9A02-663A-41EF-AC5C-2AE3207C4B57Q35794435-52B510B9-120A-481C-8CBD-63D6D54ED603Q37076434-3A668855-5C39-40CF-AC4C-D5283A2424F5Q37552020-901C51E3-81E0-4A78-B0AE-3D6763AF5EA4Q37923939-A4E97D2D-B58E-4B7D-825D-F32290A8EF6AQ37974844-5EEB1033-0B4B-4D67-A422-33E5052926FEQ37995804-3EF1937B-05A9-4762-8D8A-9025EB9A5502Q38122703-EF443FB9-ECA7-4EAF-91F2-4DCA7FA86B1AQ39083031-412927F6-D6A6-44A2-B9BB-6BF46BB32AEEQ39399799-9D0AE4CF-1E4F-453E-AF4E-8A6AC31D17D5Q40298579-4911C530-1589-44EA-AF3E-88986ABE5BBBQ41012858-460C07EC-899A-4CED-B3A0-7BC4AC1FE422Q42051491-4969CD17-B750-4EB8-AE74-83E80FD59A8DQ42689905-44DF408B-B525-4A26-8991-74B30B1ED3F0Q48238395-53F8CFA4-2CC8-4DC5-A94B-21802B3A5D47Q49209843-E5CE8729-729A-4054-BF88-887E569854FFQ53059564-4DFFD208-A1D4-42C1-892A-B9F1DF1E100AQ54112495-642CE92C-B058-4F99-B177-12DB38264C01Q54559779-3B46127E-5338-453A-90E4-47AC2F4FFDFEQ58023808-CFD148FE-BC0E-4983-BB74-FF2AF3C18B0EQ58455666-3B5A5260-A591-46EA-BC18-D8F7FF09416DQ58734773-62F577E2-A5AA-4508-B247-11A0E1F1BFD3
P2860
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The most commonly reported var ...... ) is not a somatic alteration.
@en
The most commonly reported variant in ASXL1
@nl
type
label
The most commonly reported var ...... ) is not a somatic alteration.
@en
The most commonly reported variant in ASXL1
@nl
prefLabel
The most commonly reported var ...... ) is not a somatic alteration.
@en
The most commonly reported variant in ASXL1
@nl
P2093
P2860
P356
P1433
P1476
The most commonly reported var ...... ) is not a somatic alteration.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2010.144
P577
2010-07-01T00:00:00Z
P6179
1015952145